KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Work In Process (2019 - 2025)

Historic Work In Process for Ionis Pharmaceuticals (IONS) over the last 7 years, with Q1 2025 value amounting to $8.7 million.

  • Ionis Pharmaceuticals' Work In Process rose 4484.02% to $8.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 4484.02%. This contributed to the annual value of $6.7 million for FY2024, which is 2194.63% up from last year.
  • As of Q1 2025, Ionis Pharmaceuticals' Work In Process stood at $8.7 million, which was up 4484.02% from $6.7 million recorded in Q4 2024.
  • In the past 5 years, Ionis Pharmaceuticals' Work In Process ranged from a high of $8.7 million in Q1 2025 and a low of $954000.0 during Q2 2021
  • Its 5-year average for Work In Process is $4.4 million, with a median of $3.9 million in 2022.
  • Its Work In Process has fluctuated over the past 5 years, first crashed by 7251.51% in 2021, then soared by 31163.52% in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' Work In Process (Quarter) stood at $5.8 million in 2021, then crashed by 63.45% to $2.1 million in 2022, then skyrocketed by 159.7% to $5.5 million in 2023, then increased by 21.95% to $6.7 million in 2024, then skyrocketed by 30.92% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q1 2025, $6.7 million for Q4 2024, and $6.7 million during Q3 2024.